Rapid Growth In Liver Cancer Therapeutics Global Market Anticipated To Reach $5.50 Billion By 2029

June 18, 2025 10:42 AM BST | By EIN Presswire
 Rapid Growth In Liver Cancer Therapeutics Global Market Anticipated To Reach $5.50 Billion By 2029
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 18, 2025 /EINPresswire.com/ -- The liver cancer therapeutics market size has witnessed significant growth in recent years, driven by factors like rising healthcare expenditure globally, expanding health insurance coverage in developing countries, and increasing prevalence of obesity and diabetes. The market is projected to surge from $2.52 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate CAGR of 17.1%.

What Are The Projections For The Future Growth Of The Liver Cancer Therapeutics Market?
Rapid growth is expected in the liver cancer therapeutics market in the few next years, as it is projected to reach $5.50 billion by 2029, registering a CAGR of 16.8%. This forecasted growth can be attributed to the rising global incidence of liver cancer, high prevalence of hepatitis B and C infections, increase in alcohol-related liver disease, and growing adoption of immunotherapy approaches.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24283&type=smp

What's Driving The Growth In The Liver Cancer Therapeutics Market?
A prominent driver in the growth of the liver cancer therapeutics market is the surge in the incidence of hepatitis B infections, a viral disease primarily affecting the liver and contributing to both short-term acute and long-term chronic health complications, including liver cancer. The virus, often spread through the sharing of contaminated needles and syringes, leads to persistent liver inflammation and cellular damage, significantly increasing the risk of malignant liver conditions over time.

Who Are The Key Industry Players In The Liver Cancer Therapeutics Market?
Major companies operating within this liver cancer therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, and Bayer AG, among others. These players, along with companies like Bristol-Myers Squibb and AstraZeneca PLC, are focusing on developing innovative therapies like prescription immunotherapy medications, aiming to provide long-lasting effects and combat diseases like cancer and chronic infections.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/liver-cancer-therapeutics-global-market-report

How Is The Liver Cancer Therapeutics Market Segmented?
The liver cancer therapeutics market report details segmentation by type, therapy type, distribution channel type, and end-users. Subsegments are also included, offering a detailed breakdown in relation to hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other types.

What Does The Regional Breakdown Look Like For The Liver Cancer Therapeutics Market?
North America represented the largest region in the liver cancer therapeutics market in 2024. However, Asia-Pacific is anticipated to be the fastest-growing region moving forward. Additional areas covered in the report include Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Liver Diseases Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Human Liver Model Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next